Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(23):1743-1744; doi:10.1093/jnci/94.23.1743
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Theisen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theisen, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 23, 1743-1744, December 4, 2002
© 2002 Oxford University Press

NEWS

Melanoma Treatment Activates Immune System Against Cancer

Christine Theisen

The first 10% of the full text of this article appears below.

Hoping to overcome a history of false steps and small advances, a research team at the National Cancer Institute recently reported that adoptive transfer—extracting immune cells from a patient, activating the cells to attack tumor cells, and injecting the cells back into the patient—showed clear tumor responses in six of 13 patients with terminal metastatic melanoma.

T lymphocytes, or T cells, are responsible for cell-mediated immunity. The basic premise of this study was to increase the number of T cells within the body. The new method for growing T cells is the most recent step in the decades-long and ongoing search for new ways to treat cancer besides the traditional surgery, chemotherapy, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
U. Haug, M. N. Wente, C. M. Seiler, D. Rothenbacher, M. W. Buchler, and H. Brenner
Tumor m2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting.
Clin. Chem., April 1, 2006; 52(4): 782 - 784.
[Full Text] [PDF]